Anders Karlén, Professor in Computer-aided drug design, Uppsala University, Sweden, is presently the overall medicinal chemistry project leader for drug discovery efforts currently directed at five different anti-bacterial targets at Uppsala University. Several of these projects have been run within EU framework 6 and 7 programmes. Since February 2014 he is the Leader of the Managing Entity and co-coordinator of the €85 million, 6 year, Innovative Medicines Initiative (IMI) project ENABLE (European Gram Negative Antibacterial Engine). The ENABLE project, within IMI’s New Drugs for Bad Bugs (ND4BB) programme, is working to advance the development of potential antibiotics against Gram-negative bacteria. The ultimate goal is to take at least one clinical candidate into a Phase I clinical study.
Mr. Karlén will be speaking at the World Anti-Microbial Resistance Congress USA 2016 about ‘IMI-ENABLE: A European Antibacterial Drug Discovery Platform’. This session will cover creating a collaborative drug discovery platform for early stage molecules that have potential to become drug candidates and treat gram-negative infections, how ENABLE can advance the development of potential antibiotics against gram-negative bacteria, and experiences from working in a public-private partnership such as ENABLE. To hear more from Anders Karlén and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016, held September 8-9 in Washington, DC.